Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 in advanced solid tumors
NCT03478995Phase 1Completed
- Sponsor
- Genexine
- Start
- Mar 2018
- Primary completion
- Mar 2020
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efineptakin alfa in solid tumor, sponsored by Genexine. Primary endpoints: Dose Limiting Toxicity at 24 months, Adverse Events at 24 months and 1 more. Started Mar 2018; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03478995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478995.